Dudediligence.

Repligen Corporation

RGENNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$154.9MSep ’24$167.5MDec ’24$169.2MMar ’25$182.4MJun ’25$188.8MSep ’25$197.9MDec ’25$194.3MMar ’26$204.1MJun ’26
Net income, by quarter
−$654,000Sep ’24−$33.9MDec ’24$5.8MMar ’25$14.9MJun ’25$14.9MSep ’25$13.3MDec ’25$8.3MMar ’26$5.0MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$670.5M$801.5M$632.4M$634.4M$738.3M
Gross profit$391.3M$455.7M$278.4M$274.6M$386.2M
Operating income$167.2M$224.7M$47.7M−$35.1M$55.2M
Net income$128.3M$186.0M$35.6M−$25.5M$48.9M
Operating cash flow$119.0M$172.1M$113.9M$175.4M$117.4M
Free cash flow$51.9M$87.2M$77.7M$149.7M$93.9M
Cash$603.8M$523.5M$751.3M$757.4M$566.0M
Debtnone on filenone on filenone on file$525.6M$542.2M
Shares outstanding55.3M55.6M55.8M56.1M56.3M